10062 related articles for article (PubMed ID: 1831084)
1. [Active specific immunotherapy of cancer using anti-idiotypic monoclonal antibodies].
Castello G; D'Alessio V
Clin Ter; 1991 May; 137(3):155-67. PubMed ID: 1831084
[TBL] [Abstract][Full Text] [Related]
2. The anti-idiotype vaccines for immunotherapy.
Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
Curr Opin Mol Ther; 2001 Feb; 3(1):63-9. PubMed ID: 11249733
[TBL] [Abstract][Full Text] [Related]
3. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
4. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
5. [Clinical trial of anti-idiotypic monoclonal antibodies in advanced melanoma].
Kageshita T; Hirai S; Ono T
Gan To Kagaku Ryoho; 1994 Feb; 21(2):163-9. PubMed ID: 8311486
[TBL] [Abstract][Full Text] [Related]
6. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
[TBL] [Abstract][Full Text] [Related]
8. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.
Barrios Y; Cabrera R; Yáñez R; Briz M; Plaza A; Forés R; Fernández MN; Díaz-Espada F
Haematologica; 2002 Apr; 87(4):400-7. PubMed ID: 11940484
[TBL] [Abstract][Full Text] [Related]
9. Immunological approaches to tumor therapy. Monoclonal antibodies, tumor vaccines, and anti-idiotypes.
Hellström KE; Hellström I
Targeted Diagn Ther; 1989; 2():1-39. PubMed ID: 2519542
[No Abstract] [Full Text] [Related]
10. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
11. Anti-idiotype antibodies in cancer treatment.
de Cerio AL; Zabalegui N; Rodríguez-Calvillo M; Inogés S; Bendandi M
Oncogene; 2007 May; 26(25):3594-602. PubMed ID: 17530013
[TBL] [Abstract][Full Text] [Related]
12. Anti-idiotype MoAb effective in B-cell non-Hodgkin's lymphoma.
Oncology (Williston Park); 1994 Jun; 8(6):50, 79. PubMed ID: 8074982
[No Abstract] [Full Text] [Related]
13. Experimental and clinical studies with active specific immunotherapy.
Livingston PO
Prog Clin Biol Res; 1989; 288():309-21. PubMed ID: 2654953
[TBL] [Abstract][Full Text] [Related]
14. Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.
Fagerberg J; Hjelm AL; Ragnhammar P; Frödin JE; Wigzell H; Mellstedt H
Cancer Res; 1995 May; 55(9):1824-7. PubMed ID: 7728746
[TBL] [Abstract][Full Text] [Related]
15. Current concepts in immunotherapy for the treatment of colorectal cancer.
Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
[TBL] [Abstract][Full Text] [Related]
16. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.
Robins RA; Denton GW; Hardcastle JD; Austin EB; Baldwin RW; Durrant LG
Cancer Res; 1991 Oct; 51(19):5425-9. PubMed ID: 1913661
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of malignant melanoma.
Oratz R; Bystryn JC
Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
[TBL] [Abstract][Full Text] [Related]
18. [Antibody and immunotherapy in oncology. Which patients benefit?].
Schlimok G
MMW Fortschr Med; 2001 Jun; 143(25):24-8. PubMed ID: 11468992
[TBL] [Abstract][Full Text] [Related]
19. Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics.
Wang X; Luo W; Foon KA; Ferrone S
Cancer Chemother Biol Response Modif; 2001; 19():309-26. PubMed ID: 11686020
[No Abstract] [Full Text] [Related]
20. Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies.
Steinitz M; Tamir S; Frödin JE; Lefvert AK; Mellstedt H
J Immunol; 1988 Nov; 141(10):3516-22. PubMed ID: 2846688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
